Michael Ljungberg

Prof. Michael Ljungberg

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2015 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
MLMichael Ljungberg
Michael Ljungberg
ACAnna Celler
Anna Celler
MKMark W. Konijnenberg
Mark W. Konijnenberg
KEKeith F. Eckerman
Keith F. Eckerman
YDYuni K. Dewaraja
Yuni K. Dewaraja
KSKatarina Sjögreen-Gleisner
Katarina Sjögreen-Gleisner
Accuracy of absorbed dose calculations in personalized internal radionuclide therapy is directly related to the accuracy of the activity (or activity concentration) estimates obtained at each of the imaging time points. MIRD Pamphlet No. 23 presented a general overview of methods that are required for quantitative SPECT imaging. The present document is next in a series of isotope-specific guidelines and recommendations that follow the general information that was provided in MIRD 23. This paper focuses on 177-Lu (Lutetium) and its main application in radiopharmaceutical therapy.

1 January 2018 in British Journal of Radiology
Verified
Journal Article
Closed access
MLMichael Ljungberg
Michael Ljungberg
PPP Hendrik Pretorius
P Hendrik Pretorius
Functional nuclear medicine imaging with single-photon emission CT (SPECT) in combination with anatomical CT has been commercially available since the beginning of this century. The combination of the two modalities has improved both the sensitivity and specificity of many clinical applications and CT in conjunction with SPECT that allows for spatial overlay of the SPECT data on good anatomy images. Introduction of diagnostic CT units as part of the SPECT/CT system has also potentially allowed for a more cost-efficient use of the equipment. Most of the SPECT systems available are based on the well-known Anger camera principle with NaI(Tl) as a scintillation material, parallel-hole collimators and multiple photomultiplier tubes, which, from the centroid of the scintillation light, determine the position of an event. Recently, solid-state detectors using cadmium–zinc–telluride became available and clinical SPECT cameras employing multiple pinhole collimators have been developed and introduced in the market....

1 May 2012 in Seminars in Nuclear Medicine
Verified
Journal Article
Closed access
EFEric C. Frey
Eric C. Frey
JHJohn L. Humm
John L. Humm
MLMichael Ljungberg
Michael Ljungberg

18 July 2011 in Acta Oncologica
Verified
Journal Article
Closed access
PDF file
MLMichael Ljungberg
Michael Ljungberg
KSKatarina Sjögreen-Gleisner
Katarina Sjögreen-Gleisner
Background. Dosimetry in radionuclide therapy estimates delivered absorbed doses to tumours and ensures that absorbed dose levels to normal organs are below tolerance levels. One procedure is to determine time-activity curves in volumes-of-interests from which the absorbed dose is estimated using SPECT with appropriate corrections for attenuation, scatter and collimator response. From corrected SPECT images the absorbed energy can be calculated by (a) assuming kinetic energy deposited in the same voxel where particles were emitted, (b) convolve with point-dose kernels or (c) use full Monte Carlo (MC) methods. A question arises which dosimetry method is optimal given the limitations in reconstruction- and quantification procedures. Methods. Dosimetry methods (a) and (c) were evaluated by comparing dose-rate volume histograms (DrVHs) from simulated SPECT of 111In, 177Lu, 131I and bremsstrahlung from 90Y to match true dose rate images. The study used a voxel-based phantom with different tumours in the liver. SPECT reconstruction was made using an iterative OSEM method and MC dosimetry was performed using a charged-particle EGS4 program that also was used to determined true absorbed dose rate distributions for the same phantom geometry but without camera limitations. Results. The DrVHs obtained from SPECT differed from true DrVH mainly due to limited spatial resolution. MC dosimetry had a marginal effect because the SPECT spatial resolution is in the same order as the energy distribution caused by the electron track ranges. For 131I, full MC dosimetry made a difference due to the additional contribution from high-energy photons. SPECT-based DrVHs differ significantly from true DrVHs unless the tumours are considerable larger than the spatial resolution. Conclusion. It is important to understand limitations in quantitative SPECT images and the reasons for apparent heterogeneities since these have an impact on dose-volume histograms. A MC-based dosimetry calculation from SPECT images is not always warranted.

15 November 2016 in Biomedicines
Verified
Journal Article
Open access
PDF file
MLMichael Ljungberg
Michael Ljungberg
KGKatarina Sjögreen Gleisner
Katarina Sjögreen Gleisner
For treatment of systemic malignancies, when external radiation therapy is not applicable, radionuclide therapy can be an alternative. In this form of therapy, radionuclides are administered to the patient, often in a form where the radionuclide is labelled to a molecule that plays the active part in the localization of the tumor. Since the aim is to impart lethal damage to tumor cells while maintaining possible side-effects to normal tissues at tolerable levels, a proper and accurate personalized dosimetry should be a pre-requisite. In radionuclide therapy, there is a need to measure the distribution of the radiopharmaceutical in vivo, as well as its re-distribution over time, in order estimate the total energy released in radioactive decays and subsequent charged-particle interactions, governing the absorbed dose to different organs and tumors. Measurements are usually performed by molecular imaging, more specifically planar and SPECT (Single-Photon Emission Computed Tomography) imaging, combined with CT. This review describes the different parts in the dosimetry chain of radionuclide therapy. Emphasis is given to molecular imaging tools and the requirements for determining absorbed doses from quantitative planar and SPECT images. As example solutions to the different problems that need to be addressed in such a dosimetric chain, we describe our tool, Lundadose, which is a set of methods that we have developed for personalized dosimetry.

26 July 2018 in IEEE Transactions on Radiation and Plasma Medical Sciences
Verified
Journal Article
Open access
MLMichael Ljungberg
Michael Ljungberg
KGK. Sjogreen Gleisner
K. Sjogreen Gleisner
Radionuclide therapy is the use of radioactive drugs for internal radiotherapy, mainly for the treatment of metastatic disease. As opposed to systemic cancer therapies in general, the use of radioactively labeled drugs results not only in a targeted therapy but also the possibility of imaging the distribution of the drug during therapy. From such images, the absorbed doses delivered to tumors and organs at risk can be calculated. Calculation of the absorbed dose from 3-D images such as single-photon emission computed tomography (SPECT)/CT, and in some cases positron emission tomography (PET)/CT, relies on image-based activity quantification. Quantification is accomplished by modeling the physics involved in the image-formation process, and applying image-processing methods. From a time-sequence of such quantitative images, the absorbed doses are then calculated. Although individual-patient dosimetry is a standard component of other forms of radiotherapy, it is still overlooked in the majority of radionuclide therapies. In this review, we summarize the physical and technical problems that need to be addressed in image-based dosimetry. The focus is on SPECT, since most of the radionuclides used are single-photon emitters, although the use of PET is also discussed. Practical issues of relevance for the practical implementation of personalized dosimetry in radionuclide therapy are also highlighted.